Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy

Marc A. Bjurlin; Samir S. Taneja

doi:10.1016/j.ucl.2017.07.012

Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy

Marc A. Bjurlin, Samir S. Taneja

Research output: Contribution to journal › Review article › peer-review

Abstract

Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.

Original language	English (US)
Pages (from-to)	535-546
Number of pages	12
Journal	Urologic Clinics of North America
Volume	44
Issue number	4
DOIs	https://doi.org/10.1016/j.ucl.2017.07.012
State	Published - Nov 2017

Keywords

MRI
MRI-ultrasonography fusion
Prebiopsy
Risk assessment
Targeted biopsy

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.ucl.2017.07.012

Fingerprint Dive into the research topics of 'Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy'. Together they form a unique fingerprint.

Cite this

@article{3ba58869b5f54fc98e7e08641969f338,

title = "Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy",

abstract = "Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.",

keywords = "MRI, MRI-ultrasonography fusion, Prebiopsy, Risk assessment, Targeted biopsy",

author = "Bjurlin, {Marc A.} and Taneja, {Samir S.}",

year = "2017",

month = nov,

doi = "10.1016/j.ucl.2017.07.012",

language = "English (US)",

volume = "44",

pages = "535--546",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy

AU - Bjurlin, Marc A.

AU - Taneja, Samir S.

PY - 2017/11

Y1 - 2017/11

N2 - Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.

AB - Prostate MRI is commonly used in the detection of prostate cancer to reduce the detection of clinically insignificant disease; maximize the detection of clinically significant cancer; and better assess disease size, grade, and location. The clinical utility of MRI seems to apply to men with no prior biopsy, who have had a previous negative biopsy, and men who are candidate for active surveillance. In conjunction with traditional clinical parameters and secondary biomarkers, MRI may allow more accurate risk stratification and assessment of need for prostate biopsy.

KW - MRI

KW - MRI-ultrasonography fusion

KW - Prebiopsy

KW - Risk assessment

KW - Targeted biopsy

UR - http://www.scopus.com/inward/record.url?scp=85032738096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032738096&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2017.07.012

DO - 10.1016/j.ucl.2017.07.012

M3 - Review article

C2 - 29107270

AN - SCOPUS:85032738096

VL - 44

SP - 535

EP - 546

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 4

ER -